European Psychiatry - Volume 33 - March 2016

488 / 812

S484 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Conclusions MBAT can be seen as an effective treatment method
that improves breast cancer patients’ psychological stability and
quality of life. Evaluation of treatment effects using program devel-
opment and large-scale research for future clinical application is
needed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV425
Psychosocial outcomes 3 years after
facial transplantation of a blind
patient
G. Lemmens ∗, H. Hendrickx , C. Poppe , N. Roche , P. Peeters ,
H. Vermeersch , X. Rogiers , K. Van Lierde , P. Blondeel
1 Ghent university, psychiatry and medical psychology, Ghent,
Belgium
2 Ghent university hospital, burn unit, Ghent, Belgium
3 Ghent university hospital, department of general and hepato-biliary
surgery and transplantation- transplantation centre, Ghent, Belgium
4 Ghent university hospital, department of plastic and reconstructive
surgery, Ghent, Belgium
5 Ghent university hospital, department of nephrology, Ghent,
Belgium
6 Ghent university hospital, department of head and neck and
maxilo-facial surgery, Ghent, Belgium
7 Department of speech, language and hearing science, Ghent,
Belgium
∗ Corresponding author.
Background To date, psychosocial outcomes after facial trans-
plantation are promising although long-term consequences,
outcome of blind patients and the impact on family members are
less well investigated. The aim of this study was to examine the
long-term psychosocial of a blind patient and his partner 2 and 3
years after facial transplantation.
Methods Depressive and anxiety symptoms, hopelessness, cop-
ing, resilience, illness cognitions, marital support, dyadic adjust-
ment, family functioning and quality of life of the patient and the
partner were assessed before and 2 and 3 years after transplanta-
tion. Reliable change index (RCI) was further calculated to evaluate
the magnitude of change.
Results Most psychological, marital and family scores of both the
patient and the partner remained within a normative and healthy
range at follow-up. Resilience (RCI: 2.5 & 3.4 respectively), affective
responsiveness (RCI: −4.1 & −3.2 respectively), physical quality of
life (RCI: 8.7 & 7.2 respectively) and helplessness (RCI: −2.2 & −2.9
respectively) of the patient improved at 2 and 3 years follow-up.
Further, dyadic cohesion (RCI: 2.4) of the patient improved at 2
years whereas marital depth (RCI: −2.0) of the partner decreased
at 3 years.
Conclusions The results of this study point to positive long-term
psychosocial outcomes of a blind patient and his partner after facial
transplantation. Further, they may underscore the importance of
patient selection, social support and involvement of family mem-
bers in treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV426
Alternative treatment options for
lithium-induced nephrogenic
diabetes insipidus
S. López-Romeo ∗, G. Ledesma-Iparraguirre
Parc Sanitari Sant Joan de Déu, psychiatry, Barcelona, Spain
∗ Corresponding author.
Introduction Lithium is currently a drug of choice for treating per-
sons with bipolar disorder and is widely used in this population.
Approximately, 30% of patients taking lithium experience at least
one episode of lithium toxicity. Treatment of acute toxicity involves
correction of electrolyte abnormalities, volume repletion followed
by forced diuresis, and dialysis in severe cases. A case report is
described and it is reviewed some alternative treatment options
before considering withdrawal of lithium treatment in lithium-
induced nephrogenic diabetes insipidus.
Case report A 58-year-oldwoman diagnosed of hypertension and
bipolar disorder for 20 years. At first, she was controlled with val-
proic acid until she suffered a manic episode which required a
mood stabilizer switch. She started a treatment with lithium 1200
mg/day and olanzapine to 10 mg/day and was completely recov-
ered. After a year of stabilization, olanzapine was retired and she
maintained stabilized with lithium 1000 mg/day during last 17
years. During last 8 months, she suffered polydipsia and polyuria
(4 L/day). She was diagnosed of nephrogenic diabetes insipidus.
Some measures like liquid restriction, lithium monodose and low
sodium diet were carried out, obtaining a partial response. Tak-
ing into account, she was stabilised with lithium for many years,
it was decided to introduce hydrochlorothiazide 25 mg/day, clini-
cal and analytical resolution of nephrogenic diabetes insipidus was
obtained. A year later, she maintains psychopathological stabiliza-
tion, without any lithium secondary effects.
Conclusion Some treatment options for lithium-induced nephro-
genic diabetes insipidus could be introducing thiazides, amiloride,
indomethacin, desmopressin or carbamazepine, instead of with-
drawal lithium.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV427
New interferon-free therapies on
HCV+ chronic hepatitis: Overcoming
psychiatric side effects in a real world
setting
M. Moneglia ∗, A. Santangelo , A. Ballerini , V. Ricca ,
A.L. Zignego
1 Azienda Ospedaliero-Universitaria Careggi, department of
neuroscience- psychology- drug research and child health, Florence,
Italy
2 Azienda Ospedaliero-Universitaria Careggi, center for systemic
manifestations of hepatitis viruses MASVE- department of
experimental and clinical medicine, Florence, Italy
∗ Corresponding author.
Introduction Interferon-alpha (IFN ) was the backbone therapy
for HCV+ related chronic hepatitis (CH-C). However, it was asso-
ciated with significant neuropsychiatric side effects and impaired
health-related quality of life. Second Generation IFN -free direct-
acting antiviral agents (DAAs) seem to be associated with fewer
side effects, better tolerability, high efficacy rates and better patient
reported outcomes (PROs) [Younoussi, 2014].
Aims To describe the neuropsychiatric symptoms and PROs dur-
ing SecondGenerationDAAs plus ribavirin oral treatment in a group
of CH-C real world patients.
Methods Nineteen CH-C outpatients, scheduled for IFN -free
treatment, were assessed at enrolment (T0), at 4 (T1) and at 12 (T2)
weeks, the end of treatment, by means of MDRS, HAM-D, HAM-
A, MRS, Y-BOCS and SF-36. A pharmacological therapy, based on
clinical evidence, was provided at psychiatric symptoms onset.
Results During the treatment, we didn’t report any worsening in
the administred psychometric scales. Furthermore, we observed a
general improvement at week 12 (T2), statistically significant only
for MRS (P < 0.05). Any statistically significant difference was found
for SF-36 mean scores comparing T0, T1 and T2. However, SF-36